Literature DB >> 33134512

Identification of a novel mutation in ATP13A2 associated with a complicated form of hereditary spastic paraplegia.

Yasuko Odake1, Kishin Koh1, Yoshihisa Takiyama1, Hiroyuki Ishiura1, Shoji Tsuji1, Masahito Yamada1, Mitsuhiro Yoshita1.   

Abstract

OBJECTIVE: To establish molecular diagnosis for a family with a complicated form of autosomal recessive hereditary spastic paraplegia with intellectual disability, cognitive decline, psychosis, peripheral neuropathy, upward gaze palsy, and thin corpus callosum (TCC).
METHODS: Physical examinations, laboratory tests, structural neuroimaging studies, and exome sequence analysis were carried out.
RESULTS: The 3 patients exhibited intellectual disability and progressive intellectual decline accompanied by psychiatric symptoms. Gait difficulty with spasticity and pyramidal weakness appeared at the ages of 20s-30s. Brain MRI revealed TCC with atrophic changes in the frontotemporal lobes, caudate nuclei, and cerebellum. Exome sequence analysis revealed a novel homozygous c.2654C>A (p. Ala885Asp) variant in the ATP13A2, a gene responsible for a complicated form of hereditary spastic paraplegia (SPG78), Kufor-Rakeb syndrome, and neuronal ceroid lipofuscinosis. The predominant clinical presentations of the patients include progressive intellectual disability and gait difficulty with spasticity and pyramidal weakness, consistent with the diagnosis of SPG78. Of note, prominent psychiatric symptoms and extrapyramidal signs including rigidity, dystonia, and involuntary movements preceded the spastic paraparesis.
CONCLUSIONS: Our study further broadens the clinical spectrum associated with ATP13A2 mutations.
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Entities:  

Year:  2020        PMID: 33134512      PMCID: PMC7577544          DOI: 10.1212/NXG.0000000000000514

Source DB:  PubMed          Journal:  Neurol Genet        ISSN: 2376-7839


Hereditary spastic paraplegias (HSPs) are neurodegenerative disorders characterized by slowly progressing spasticity and pyramidal weakness of the lower limbs. Clinically, HSPs are classified into pure and complicated forms. Patients with pure HSPs show lower limb spasticity associated with pyramidal weakness alone, whereas patients with complicated forms show additional neurologic signs. To date, SPG1–SPG80 have been described as the genetic loci for HSP. Mutations in the ATP13A2 gene were originally identified in patients with Kufor-Rakeb syndrome (KRS), a rare autosomal recessive form of juvenile-onset atypical parkinsonism associated with supranuclear gaze palsy, spasticity, and dementia,[1] and subsequently reported in those with early onset Parkinson disease (PARK9),[2,3] neuronal brain iron accumulation,[4] and neuronal ceroid lipofuscinosis (CLN12).[5] Recently, Estrada-Cuzcano et al.[6] described cases of complicated HSP (SPG78) with c.1550C>T (p.Thr517Ile), c.364C>T (p.Gln122*), or c.1345C>T/c.3418C>T (p.Arg449*/p.Gln1140*) (NM 022089) in the ATP13A2 gene. Functional analysis of ATP13A2 with the p.Thr517Ile missense variant confirmed the loss of function of ATP13A2.[6] We have recently experienced 3 sibling cases in one family with a complicated form of HSP accompanied by intellectual disability and psychiatric symptoms. Exome sequence analysis of the proband revealed a novel homozygous mutation of c.2654C>A (p.Ala885Asp) in the ATP13A2 gene. We herein report the detailed clinical presentations of the 3 cases showing considerable overlaps with those described in other ATP13A2-related disorders.

Clinical manifestations of the 3 sibling cases

Patient 1

The pedigree chart of the family is presented in figure 1. The parents of the 3 siblings (patients 1, 2, and 3) were first cousins. Her father died of cerebral infarction at the age of 60 years, and her mother had dementia with anxiety along with lumbar spondylosis around the age of 76 years. Patient 1(II-1) did not show any abnormalities at birth. Intellectual disability was noticed in her childhood and she went to a special support class. Her motor function, however, developed normally. At the age of 19 years, she experienced relationship and paranoid delusions, leading to the diagnosis of schizophrenia at a local general hospital. She was prescribed several antipsychotics. She developed a gait abnormality at the age of 29 years, and dystonia was observed in the extremities, especially in the upper extremities at the age of 30. There were neither cerebellar signs nor nystagmus. She was noticed to have rigidity in her extremities and supranuclear gaze palsy at the age of 33. Later, she exhibited spasticity in the lower limbs. Her intellectual impairment and gait disturbance gradually deteriorated, and she became bedridden around the age of 40. Partial seizures and generalized tonic seizures appeared around the age of 52. Later, she was diagnosed as having HSP at our hospital. She exhibited spasticity and muscle atrophy in the lower limbs, generalized increased tendon reflexes, extensor plantar reflexes, and involuntary movement in her upper trunk. Brain MRI taken at the age of 48 showed thin corpus callosum (TCC) and atrophic changes in frontotemporal lobes, caudate nuclei, cerebellum, and brainstem (figure 2A). Brain MRI did not show iron accumulation in the putamen or caudate nucleus. Routine blood test results were within the normal limits. There were no lesions in the spinal X rays. There was no hepatosplenomegaly.
Figure 1

Pedigree chart of the family

Squares and circles indicate men and women, respectively. A diagonal line through a symbol indicates a deceased individual. Affected individuals are indicated by filled symbols. II-2 had intellectual disability and gait disturbance at the age of 13 and died at age of 17.

Figure 2

Neuroimaging studies of the patients

(A) T1-weighted brain MRI scans of patient 1 at the age of 48. TCC and atrophic changes in frontotemporal lobes, caudate nuclei, cerebellum, and brainstem are shown. (B) T1-weighted brain MRI scans of patient 2 at the age of 46. TCC and atrophic changes in frontotemporal lobes, caudate nuclei, cerebellum, and brainstem are shown. Brainstem atrophy was also observed. (C) Brain CT scans of patient 3 at the age of 45. Atrophic changes in frontotemporal lobes, caudate nuclei, cerebellum, and brainstem are shown. TCC = thin corpus callosum.

Pedigree chart of the family

Squares and circles indicate men and women, respectively. A diagonal line through a symbol indicates a deceased individual. Affected individuals are indicated by filled symbols. II-2 had intellectual disability and gait disturbance at the age of 13 and died at age of 17.

Neuroimaging studies of the patients

(A) T1-weighted brain MRI scans of patient 1 at the age of 48. TCC and atrophic changes in frontotemporal lobes, caudate nuclei, cerebellum, and brainstem are shown. (B) T1-weighted brain MRI scans of patient 2 at the age of 46. TCC and atrophic changes in frontotemporal lobes, caudate nuclei, cerebellum, and brainstem are shown. Brainstem atrophy was also observed. (C) Brain CT scans of patient 3 at the age of 45. Atrophic changes in frontotemporal lobes, caudate nuclei, cerebellum, and brainstem are shown. TCC = thin corpus callosum.

Patient 2

Patient 2 was the younger sister of the patient 1. She had no abnormalities at birth. Intellectual disability was noticed in her childhood and she went to a special support class. Her motor function developed normally. At the age of 31, she talked to herself, exhibited forced laughing, and became increasingly irritable. She developed gait abnormality at the age of 32. She showed horizontal gaze nystagmus and rigido-akinetic clinical presentations but did not show tremor. She exhibited spasticity and muscle atrophy in the lower limbs, increased tendon reflexes in her 4 extremities, and extensor plantar reflexes. Her symptoms of intellectual impairment and gait disturbance gradually worsened, and she became bedridden at the age of 34. She was diagnosed as having HSP. At the age of 44, neurologic examination revealed severe intellectual disability and euphoria and an upward gaze limitation. She could not speak because of progressing dementia. She exhibited an involuntary movement of extending her right elbow, and her legs were in flexed positions with contracture of knee and ankle joints. She was diagnosed as having a complicated form of HSP. Brain MRI taken at the age of 46 showed TCC and atrophic changes in frontotemporal lobes, caudate nuclei, cerebellum, and brainstem (figure 2B). Brain MRI did not show iron accumulation in the putamen or caudate nucleus. Routine blood test results were within the normal limits. There were no lesions in the spinal X rays. There was no hepatosplenomegaly. She suffered from bacterial meningoencephalitis at the age of 46 but recovered by treatment with antibiotics. After this event, partial and generalized tonic seizures appeared. Later, she exhibited involuntary movement, shaking her head from side to side. Her condition gradually deteriorated, and she died of pneumonia at the age of 52.

Patient 3

Patient 3 was the youngest sister of patients 1 and 2. She had no abnormalities at birth. Intellectual disability was noticed in her childhood and she went to a special support class. Her motor function developed normally. At the age of 33, she experienced hallucinations and delusions. She presented with spastic tetraparesis and spastic gait at the age of 35. She became unable to walk in a few years. Her intellectual impairment deteriorated. At the age of 42, she had euphoria and exhibited dysarthria. She did not have any abnormal eye movements. She presented with spasticity and muscle atrophy in the lower limbs, generalized increased tendon reflexes, and extensor plantar reflexes. There was mild dysmetria in her upper limbs, and she exhibited stereotypic movements in her upper limbs and face. Owing to these movements, she frequently hit her arm against the bed fence. She was diagnosed as having a complicated form of HSP. Brain CT scan taken at the age of 45 showed atrophic changes in frontotemporal lobes, caudate nuclei, cerebellum, and brainstem (figure 2C). Routine blood test results were within normal limits. There were no lesions in the spinal X rays. There was no hepatosplenomegaly. Her condition gradually deteriorated and she died of respiratory failure at age 45.

Mutational analysis

We received approval from the National Hospital Organization, Hokuriku National Hospital Clinical Research Ethics Committee, to conduct this study and obtained written informed consent from the family for genetic testing and protocol. Exome sequence analysis was performed as described previously.[7] NM 022089 was used as the reference sequence for ATP13A2 in this study. The disease-causing variant was confirmed by primer pairs (5′-GCCCAGCTGTCATCATTTC and 5′-CCCACGTCATCTATTCTGGG).

Data availability

The raw data are available upon request.

Results

Identification of causative variant

We searched exome sequence data of patient 1 for rare variants in the known causative genes for HSP (the gene list for HSP is shown in the supplementary data, links.lww.com/NXG/A319) and identified an apparently homozygous c.2654C>A (p.Ala885Asp) variant in ATP13A2 in patients 1 and 2 (figure 3A). Analysis of the number of reads from individual exons excluded the possibility of large deletions involving exons including exon 24 in one allele (figure 3C) confirming the homozygosity of the c.2654C>A (p.Ala885Asp) variant.
Figure 3

Mutational analysis of the family

(A) Direct nucleotide sequence analysis of the PCR products obtained from patients 1, 2, and their mother showing c.2654C>A (p.Ala885Asp). Nucleotide sequence analysis of the reverse complementary strand is shown. (B) The c.2654C>A (p.Ala885Asp) involves alanine residue at codon 885 that is highly conserved among species. Conserved amino acid residues are shown by black, whereas those showing a strong conservation among species are shown by gray. Other previously reported causative variants (p.G877R and p.G892D) are shown above the amino acid sequences. (C) Comparison of RPM (reads per million mapped reads) in individual exons of ATP13A2 calculated using the results of exome sequence analysis. Log2 ratio of RPM at individual exons is shown on the y-axis, whereas the physical position of ATP13A2 on human chromosome 1 (GRCh37/hg19)) is shown on the x-axis. There are no significant differences in the RPM values of individual exons including exon 24, where the variant is located, confirming the homozygosity of the c.2654C>A (p.Ala885Asp) variant in the patients.

Mutational analysis of the family

(A) Direct nucleotide sequence analysis of the PCR products obtained from patients 1, 2, and their mother showing c.2654C>A (p.Ala885Asp). Nucleotide sequence analysis of the reverse complementary strand is shown. (B) The c.2654C>A (p.Ala885Asp) involves alanine residue at codon 885 that is highly conserved among species. Conserved amino acid residues are shown by black, whereas those showing a strong conservation among species are shown by gray. Other previously reported causative variants (p.G877R and p.G892D) are shown above the amino acid sequences. (C) Comparison of RPM (reads per million mapped reads) in individual exons of ATP13A2 calculated using the results of exome sequence analysis. Log2 ratio of RPM at individual exons is shown on the y-axis, whereas the physical position of ATP13A2 on human chromosome 1 (GRCh37/hg19)) is shown on the x-axis. There are no significant differences in the RPM values of individual exons including exon 24, where the variant is located, confirming the homozygosity of the c.2654C>A (p.Ala885Asp) variant in the patients. The variant was neither registered in gnomAD (gnomad.broadinstitute.org/) nor in the in-house database consisting of 1,261 control subjects. The variant was only registered in the integrative Japanese Genome Variation Database (ijgvd.megabank.tohoku.ac.jp/) at a very low allele frequency (0.00015). The amino acid, Ala, at codon 885 is evolutionally conserved among species (figure 3B). In silico prediction revealed a combined annotation dependent depletion score of 28.1, supporting its pathogenicity (cadd.gs.washington.edu/home).”

Discussion

The clinical presentations of the 3 patients are summarized in table. Prominent psychiatric symptoms preceding gait abnormality commonly observed in the 3 patients in this family was one of the characteristic clinical presentations. In particular, all the patients presented psychiatric symptoms such as hallucination, delusion, or increased irritability over one to 10 years before the onset of gait disturbance. Although psychiatric symptoms have previously been frequently reported in patients with KRS or PARK9,[2,3,13,14] they usually develop several years after the onset of gait disturbances or administration of antiparkinsonian drugs. Among the patients with PARK9, the one patient reported by Schneider et al.[4] is an exceptional case presenting with the psychiatric symptoms before the onset of parkinsonism. Among the patients with the clinical diagnosis of HSP with ATP13A2 mutation (SPG78), only one case of Estiar et al.[12] presented with psychiatric symptoms preceding spastic paraparesis.
Table

Clinical characteristics of patients with SPG78

Clinical characteristics of patients with SPG78 Psychiatric symptom is also observed in patients with neurodegeneration with brain iron accumulation (NBIA) presenting with progressive dystonia/parkinsonism.[15,16] Although we did not observe iron deposition in our patients, NBIA or NBIA-related diseases should also be included in a differential diagnosis for patients presenting with psychiatric symptoms accompanied by dystonia/parkinsonism. Supranuclear gaze palsy is also a characteristic finding in ATP13A2-related diseases. In addition to progressive supranuclear palsy and parkinsonism linked to chromosome 17 (FTDP-17), supranuclear gaze palsy is also observed in patients with Niemann-Pick disease type C (NPC) presenting with dystonia, cognitive decline, and psychiatric symptoms,[17-19] thus NPC should also be included in a differential diagnosis. TCC is an important finding in the differential diagnosis of HSP and is observed in SPG1, SPG11, SPG15, SPG21, SPG44, SPG46, SPG47, SPG49, SPG50, SPG54, SPG63, SPG66, and SPG71.[20] Becuase MRI scans revealed TCC in patients 1 and 2 in this study and one patient with SPG78 showed TCC,[6] SPG78 should also be included in the differential diagnosis of HSPs with TCC. Patient 1 initially manifested extrapyramidal symptoms. Indeed, she was initially tested for possible Wilson disease, but spastic paraparesis appeared later and became predominant over time. Patient 2 had pallidopyramidal syndrome (rigido-akinetic plus spasticity), and patient 3 had spastic tetraparesis with cognitive decline. In contrast to previous reports showing the similar clinical presentations among the siblings with the ATP13A2 variants,[6] the 3 siblings in this family exhibited similar but considerable variation in the complex clinical presentations. Thus, the present 3 sibling case falls in the continuum between the 2 extremities (HSP78 and KRS).[6,21] Intrafamilial and interfamilial variations in the clinical presentations associated with ATP13A2 mutation should be further investigated.
  21 in total

1.  PARK9-linked parkinsonism in eastern Asia: mutation detection in ATP13A2 and clinical phenotype.

Authors:  Y P Ning; K Kanai; H Tomiyama; Y Li; M Funayama; H Yoshino; S Sato; M Asahina; S Kuwabara; A Takeda; T Hattori; Y Mizuno; N Hattori
Journal:  Neurology       Date:  2008-04-15       Impact factor: 9.910

2.  Reply: Complicated hereditary spastic paraplegia due to ATP13A2 mutations: what's in a name?

Authors:  Rebecca Schüle
Journal:  Brain       Date:  2017-12-01       Impact factor: 13.501

3.  Loss-of-function mutations in the ATP13A2/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78).

Authors:  Alejandro Estrada-Cuzcano; Shaun Martin; Teodora Chamova; Matthis Synofzik; Dagmar Timmann; Tine Holemans; Albena Andreeva; Jennifer Reichbauer; Riet De Rycke; Dae-In Chang; Sarah van Veen; Jean Samuel; Ludger Schöls; Thorsten Pöppel; Danny Mollerup Sørensen; Bob Asselbergh; Christine Klein; Stephan Zuchner; Albena Jordanova; Peter Vangheluwe; Ivailo Tournev; Rebecca Schüle
Journal:  Brain       Date:  2017-02       Impact factor: 13.501

4.  Novel mutation in ATP13A2 widens the spectrum of Kufor-Rakeb syndrome (PARK9).

Authors:  H Eiberg; L Hansen; L Korbo; I M Nielsen; K Svenstrup; S Bech; L H Pinborg; L Friberg; L E Hjermind; O R Olsen; J E Nielsen
Journal:  Clin Genet       Date:  2011-07-18       Impact factor: 4.438

5.  Kufor Rakeb disease: autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia.

Authors:  David R Williams; Ali Hadeed; Amir S Najim al-Din; Abdel-Latif Wreikat; Andrew J Lees
Journal:  Mov Disord       Date:  2005-10       Impact factor: 10.338

6.  Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome.

Authors:  A S Najim al-Din; A Wriekat; A Mubaidin; M Dasouki; M Hiari
Journal:  Acta Neurol Scand       Date:  1994-05       Impact factor: 3.209

7.  ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation.

Authors:  Susanne A Schneider; Coro Paisan-Ruiz; Niall P Quinn; Andrew J Lees; Henry Houlden; John Hardy; Kailash P Bhatia
Journal:  Mov Disord       Date:  2010-06-15       Impact factor: 10.338

8.  Early co-occurrence of a neurologic-psychiatric disease pattern in Niemann-Pick type C disease: a retrospective Swiss cohort study.

Authors:  Lucia Abela; Barbara Plecko; Antonella Palla; Patricie Burda; Jean-Marc Nuoffer; Diana Ballhausen; Marianne Rohrbach
Journal:  Orphanet J Rare Dis       Date:  2014-11-26       Impact factor: 4.123

9.  Adult Niemann-Pick disease type C in France: clinical phenotypes and long-term miglustat treatment effect.

Authors:  Yann Nadjar; Ana Lucia Hütter-Moncada; Philippe Latour; Xavier Ayrignac; Elsa Kaphan; Christine Tranchant; Pascal Cintas; Adrian Degardin; Cyril Goizet; Chloe Laurencin; Lionel Martzolff; Caroline Tilikete; Mathieu Anheim; Bertrand Audoin; Vincent Deramecourt; Thierry Dubard De Gaillarbois; Emmanuel Roze; Foudil Lamari; Marie T Vanier; Bénédicte Héron
Journal:  Orphanet J Rare Dis       Date:  2018-10-01       Impact factor: 4.123

10.  ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease.

Authors:  A Di Fonzo; H F Chien; M Socal; S Giraudo; C Tassorelli; G Iliceto; G Fabbrini; R Marconi; E Fincati; G Abbruzzese; P Marini; F Squitieri; M W Horstink; P Montagna; A Dalla Libera; F Stocchi; S Goldwurm; J J Ferreira; G Meco; E Martignoni; L Lopiano; L B Jardim; B A Oostra; E R Barbosa; V Bonifati
Journal:  Neurology       Date:  2007-05-08       Impact factor: 9.910

View more
  2 in total

1.  Autosomal Recessive Spastic Paraplegia Type 78 Associated with a Homozygous Variant in the ATP13A2 Gene.

Authors:  Hussein Algahtani; Bader Shirah; Salem Alshammari; Fareeda Alghamdi; Angham Abdulrhman Abdulkareem; Muhammad Imran Naseer
Journal:  Mov Disord Clin Pract       Date:  2022-07-12

2.  ATP13A2 protects dopaminergic neurons in Parkinson's disease: from biology to pathology.

Authors:  Tao Dang; Wen-Jing Cao; Rong Zhao; Ming Lu; Gang Hu; Chen Qiao
Journal:  J Biomed Res       Date:  2022-03-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.